Immunocore Holdings plc (NASDAQ:IMCR) Position Increased by Primecap Management Co. CA

Primecap Management Co. CA raised its holdings in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 8.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,668,550 shares of the company’s stock after buying an additional 196,530 shares during the period. Primecap Management Co. CA owned about 0.05% of Immunocore worth $78,722,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its stake in Immunocore by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock worth $248,000 after purchasing an additional 960 shares during the period. GSA Capital Partners LLP acquired a new position in Immunocore in the 3rd quarter worth approximately $406,000. Alpha DNA Investment Management LLC acquired a new position in Immunocore in the 3rd quarter worth approximately $411,000. XTX Topco Ltd boosted its stake in Immunocore by 72.9% in the 3rd quarter. XTX Topco Ltd now owns 15,459 shares of the company’s stock worth $481,000 after purchasing an additional 6,516 shares during the period. Finally, Verition Fund Management LLC acquired a new position in Immunocore in the 3rd quarter worth approximately $739,000. Institutional investors and hedge funds own 84.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Morgan Stanley reaffirmed an “equal weight” rating and issued a $35.00 price objective on shares of Immunocore in a research note on Friday, March 7th. Needham & Company LLC reiterated a “buy” rating and issued a $71.00 target price on shares of Immunocore in a research report on Wednesday, March 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research report on Wednesday, March 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $65.64.

Immunocore Stock Down 5.5 %

Immunocore stock opened at $28.38 on Wednesday. The company has a market capitalization of $1.42 billion, a P/E ratio of -29.87 and a beta of 0.79. The firm’s fifty day simple moving average is $30.03 and its 200-day simple moving average is $31.22. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore Holdings plc has a 1-year low of $27.19 and a 1-year high of $66.00.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.